- Home
- ZBH
ZBH
Zimmer Biomet Holdings Inc.
as 04-18-2025 1:45pm EST
| Founded: | 1927 | Country: | United States |
| Employees: | N/A | City: | WARSAW |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $124.15 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.43 | EPS Growth: | -9.22 |
| 52 Week Low/High: | $96.58 - $123.96 | Next Earning Date: | 05-05-2025 |
| Revenue: | $7,678,600,000 | Revenue Growth: | 3.85% |
| Revenue Growth (this year): | 3.82% | Revenue Growth (next year): | 4.74% |
Stock Insider Trading Activity of Zimmer Biomet Holdings Inc. (ZBH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Winkler Lori | ZBH | SVP and CHRO | Mar 5 '25 | Sell | $104.40 | 1,443 | $150,649.20 | 8,768 |
Latest Zimmer Biomet Holdings Inc. News
ZBH Breaking Stock News: Dive into ZBH Ticker-Specific Updates for Smart Investing
Morningstar Research
4 days ago
Analyst Report: Zimmer Biomet Holdings, Inc.
Simply Wall St.
5 days ago
Zimmer Biomet Holdings (NYSE:ZBH) Proposes Officer Exculpation Amendment at Upcoming Shareholder Meeting
StockStory
8 days ago
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q4 Earnings?
PR Newswire
9 days ago
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results
Zacks
12 days ago
ZBH Stock to Gain From Volume Growth Amid Rising Costs
Morningstar Research
16 days ago
Analyst Report: Zimmer Biomet Holdings, Inc.
MT Newswires
17 days ago
Evercore ISI Adjusts Zimmer Biomet Holdings' Price Target to $116 From 110, Maintains In Line Rating
MT Newswires
18 days ago
Zimmer Biomet Gets CE Mark Approval for RibFix Advantage Fixation System
Compare ZBH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZBH Zimmer Biomet Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.